KemPharm, Inc. (now identified in the request metadata as Zevra Therapeutics) — Q2 2016 Form 10-Q
Issuer and period: The supplied filing is for KemPharm, Inc., not a company named Zevra Therapeutics. It reports the quarter and six months ended June 30, 2016; financial statements are unaudited. Amounts below are in U.S. dollars unless otherwise noted.
Business context and reporting period
KemPharm was a clinical-stage specialty pharmaceutical company developing prodrugs using its Ligand Activated Therapy platform. It had no product revenue. Its pipeline included Apadaz (hydrocodone/acetaminophen), pain candidates, ADHD candidate KP415, and a CNS candidate. As of August 9, 2016, 14,646,982 common shares were outstanding.
Financial performance and liquidity
| Metric | Q2 2016 / June 30, 2016 | Comparison |
|---|---|---|
| Revenue | $0 | $0 in Q2 2015 |
| Research and development expense | $5.0 million | $2.8 million in Q2 2015 |
| General and administrative expense | $4.3 million | $3.2 million in Q2 2015 |
| Operating loss | $9.3 million | $6.0 million in Q2 2015 |
| Net income (loss) | $9.8 million | $(29.7) million in Q2 2015 |
| Cash and cash equivalents | $27.5 million | $32.3 million at Dec. 31, 2015 |
| Restricted cash, marketable securities, long-term investments | $1.1 million, $55.1 million, $18.9 million | Restricted cash and long-term investments were nil at Dec. 31, 2015; marketable securities were $19.0 million |
The reported Q2 net income was not driven by product sales or operating performance: it included a $20.8 million favorable fair-value adjustment, principally from a decrease in derivative and warrant liabilities. For the six months, the company reported a $16.2 million operating loss and $6.8 million net income, compared with a $9.1 million operating loss and $35.7 million net loss in the first half of 2015. The six-month 2016 results included a $31.0 million fair-value gain and a $4.7 million loss on extinguishment of debt. With no revenue, profit margins are not meaningful.
For the six months, operating cash outflow was $12.1 million, versus $9.3 million in 2015. Investing cash outflow was $56.3 million, largely reflecting purchases of marketable securities and long-term investments; financing cash inflow was $63.6 million, principally from the 2021 notes. Cash and cash equivalents fell by $4.8 million during the period.
At June 30, total assets were $104.6 million and total liabilities were $104.3 million, leaving stockholders’ equity of $0.3 million. Current assets were $84.6 million and current liabilities $7.4 million. The balance sheet showed $1.9 million of current convertible notes and $90.4 million of long-term convertible notes, net; derivative and warrant liabilities were $6.0 million. The company issued $86.25 million principal amount of 5.50% convertible notes due 2021, receiving approximately $82.8 million net proceeds, and used approximately $18.6 million to repay the Deerfield term notes. Remaining Deerfield convertible debt bore 9.75% interest.
Material changes versus the prior comparable period
- Operating expenses rose: first-half R&D increased to $8.2 million from $4.9 million, and G&A to $8.0 million from $4.2 million. The filing attributes increases to development and third-party costs, Apadaz pre-commercialization and FDA-related work, personnel, and stock compensation.
- Net results shifted from a substantial loss to reported income, primarily because the fair-value adjustment changed from a $24.4 million loss in first-half 2015 to a $31.0 million gain in first-half 2016. This is a non-cash, valuation-sensitive item.
- The February 2016 notes offering raised net proceeds and funded repayment of the Deerfield term notes; the company also invested cash in marketable securities and long-term investments.
- Derivative and warrant liabilities declined from $37.8 million at year-end 2015 to $6.0 million at June 30, 2016, with the change substantially affecting reported earnings.
Outlook, commentary, risks and unusual items
- Management stated that cash, restricted cash, marketable securities and long-term investments were expected to fund operating expenses and capital expenditures for at least 24 months under its current operating plan. It also warned that assumptions could prove inaccurate and that substantial additional funding would be needed over time.
- In June 2016, the FDA issued a complete response letter for Apadaz, stating that proposed labeling did not accurately convey the abuse-deterrence study outcomes. At an August end-of-review meeting, the FDA and company discussed potential paths forward, including possible abuse-deterrence labeling; approval and timing remained uncertain. The filing reports advisory committee votes of 16–4 for approval and 18–2 against abuse-deterrent labeling.
- The company expected significant ongoing development costs and operating losses. Key risks included regulatory approval and labeling, clinical and manufacturing execution, opioid-related policy and market risks, reliance on third parties, intellectual-property challenges, and access to future financing.
- The 2021 notes are convertible and include fundamental-change repurchase and make-whole provisions; associated embedded features are remeasured at fair value and may add volatility to reported results. The Deerfield facility also contains restrictions and change-of-control provisions.
- Management reported disclosure controls and procedures were effective as of June 30, 2016, and no material change in internal control over financial reporting during the quarter. The filing disclosed no material pending litigation or off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q is filed by KemPharm, Inc.; the request metadata names Zevra Therapeutics.
- Track the FDA’s next steps on Apadaz, including whether a resubmission or appeal is pursued and what labeling claims may be available.
- Assess actual liquidity and cash burn against management’s stated 24-month runway, including the composition and maturities of investments.
- Review debt carrying values, conversion and dilution terms, interest obligations, Deerfield restrictions, and potential repurchase requirements.
- Separate operating performance from non-cash fair-value gains when evaluating reported net income and per-share results.
- Monitor development milestones, trial costs, financing needs, and any changes to the company’s pipeline or commercialization plans.